Currently Recruiting: OPTIMUM-D Study

ClinicalTrials.gov ID: NCT05017311

The purpose of the OPTIMUM-D (Optimized Predictive Treatment In Medications for Unipolar Major Depression) Study is to test whether a specific combination of biomarkers discovered during previous studies can help predict how someone experiencing a major depressive episode will respond to treatment. The study will also explore other possible biomarkers that may predict treatment response, which may help in the future development of tests that can guide treatment choice more effectively and more quickly.

Eligible participants will receive monetary compensation, antidepressant treatment, and clinical care for 12 weeks.

General Information

Patients are randomly assigned to the Allocation by Predictive Biomarker Algorithm group. Based on the outcome result from the personalized predictive biomarker algorithm, patients predicted as non-responders to escitalopram monotherapy will receive open-label escitalopram (10-20 mg/d) and blinded brexpiprazole (0.5-2 mg/d) for the first 8 weeks of the study. For the final 4 weeks of the study, patients will continue to receive both medications but the brexpiprazole will no longer be blinded.

Treatment:

Drug: Escitalopram

Drug: Brexpiprazole

Recruiting Regions

Contact Information

British Columbia

Alberta

Nova Scotia

Ontario